go-v.orgdoi

Iliac vein stenting in the management of chronic venous outflow obstruction

Matthew Machin · container not stated · 2025

  • DOI 10.25560/123749
  • Publisher OpenAlex
  • Type article
  • Issued 2025

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

· OpenAlex · article · 2025

Abstract

Background Chronic venous outflow obstruction (CVOO), encompassing post-thrombotic syndrome (PTS) and non-thrombotic iliac vein lesions (NIVL), is treated with iliac vein stenting or medical therapy. High-quality evidence on treatment success, resource use, and cost-effectiveness are limited, and randomised evidence for clinical efficacy is scarce. This thesis addresses these shortfalls.

Methods Five work packages (WP) were undertaken: A) meta-analysis of iliac vein stenting using reconstructed individual-patient data with meta-regression; B) trend analysis of deep venous procedures across England (1998–2024); C) retrospective cohort studying factors associated with successful stenting; D) multi-level Markov state-transition model to evaluate cost-effectiveness; and E) an international assessor-blinded multicentre randomised controlled trial (RCT). Results At 60 months, pooled primary patency (PP) was 61.6% for PTS (n=3,628; 95% CI 55.3–64.8) and 80.5% for NIVL (n=2,557; 95% CI 76.0–85.2).

Mean reductions in venous clinical severity score were 4.53 for PTS (n=266; 95% CI 4.00–5.05) and 4.69 for NIVL (n=723; 95% CI 4.12–5.26). In the single-centre regression, underlying pathology was significantly associated with patency, with PTS exerting the largest negative effect. Chronic venous obstruction classification grade was associated with baseline pathology and long-term patency. The incremental cost-effectiveness ratio (ICER) for stenting was £15,150.37 for PTS and £9,449.07 for NIVL. Deterministic sensitivity analysis identified health-utility gain as the dominant driver; stenting was not cost-saving.

The BEST trial activated 6 sites, accrued 15.5 active-centre months, and recruited 10 participants in a 6-month internal pilot. After loss of funding, the trial was redesigned but failed to recruit further due to limited equipoise and patient preference. Conclusion Non-randomised evidence suggests early safety and clinical efficacy of stenting in CVOO, but PTS has poor long-term patency with frequent reintervention. While ICERs appear below the NICE threshold, uncertainty around utility gains is substantial. A RCT remains necessary to determine benefit over medical therapy.

Open the resolved locator · 10.25560/123749

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:17 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://hdl.handle.net/10044/1/123749
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.